ClinicalTrials.gg
RecruitingNCT06306183VicamedUpdated Mar 2, 2026

Effect of Vitamin C on Pain Reduction After an Emergency Department Visit

An interventional study of Vitamin C and Placebo in Pain, Acute, sponsored by Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal. Recruiting at 4 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 61 studies in Acute Pain with a site in Canada — 8 open to participants now, 10 under way, 1 of them phase 3. Acute Pain · Canada.

Planned enrollment
10th of 54
204 · median 80
Started
2025
with 4 others
No phase
31 of 61
4 open now
Registered
55th of 61
by date
Lead sponsor
5 of 61
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal

Among the 61 studies in Acute Pain with a site in Canada, this one is the 10th largest by planned enrollment of the 54 interventional ones that give a count, is one of 5 that started in 2025, is one of 31 with no phase, and was the 55th registered.

Acute Pain

1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

8 of the 61 studies in Acute Pain with a site in Canada are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Acute Pain with a site in Canada, or all of them as a file.
02

Study summary

Musculoskeletal (MSK) injuries such as sprains, strains, bruises, and fractures are among the most common reasons people visit the emergency department. These injuries often cause significant pain in the first few days, making it difficult to move, work, or sleep. Usual pain medications like ibuprofen or acetaminophen can help, but they are not safe or effective for everyone. Some people cannot take them because of heart, kidney, stomach, or liver problems. Others still experience strong pain despite treatment. Because of these limits, some patients receive opioids, which can cause side effects and carry a risk of dependence. Safer and more accessible options are needed.

Vitamin C is widely known for supporting the immune system, but research suggests it may also help reduce pain and inflammation. Studies in surgical patients have shown that vitamin C can lower pain levels, reduce the need for opioids, and support healing. These effects may be linked to its antioxidant properties and its role in tissue repair. However, no study has tested whether vitamin C can help people with recent MSK injuries treated in the emergency department.

The VICAMED study aims to answer this question. Adults arriving with an MSK injury that occurred within the past 48 hours can participate if they have at least moderate pain. Participants are randomly assigned to receive either vitamin C or a placebo. The first dose is given in the emergency department, followed by twice daily capsules for three days. Pain is measured using a simple 0-100 scale, recorded in an electronic or paper diary. A follow-up on day six helps the research team understand each participant's recovery, medication use, and overall experience.

Vitamin C is inexpensive, widely available, and very safe at the doses used in this study. If it proves effective, it could offer a simple, low risk option to help patients manage pain after an MSK injury and reduce the need for opioids in emergency care.

Read the detailed description

Background:

Acute musculoskeletal (MSK) injuries are a major cause of emergency department (ED) visits and frequently result in moderate to severe pain during the first days following presentation. First-line analgesics such as NSAIDs and acetaminophen have important contraindications and safety limitations, particularly in older adults and patients with comorbidities, underscoring the need for safe, accessible, opioid-sparing alternatives. Preclinical studies and postoperative trials suggest that vitamin C (ascorbic acid) may provide analgesic and anti-inflammatory effects through reduction of oxidative stress, protection of neural tissues, and enhanced collagen synthesis. Meta-analyses have reported reductions in postoperative opioid consumption, pain intensity, and inflammatory markers. However, no randomized controlled trial has evaluated vitamin C for acute traumatic MSK pain in the ED.

Objective:

The primary objective is to determine whether a single 900 mg oral dose of vitamin C reduces pain intensity one hour after administration compared with placebo in adults presenting with acute MSK injuries. The main secondary objective is to assess whether 900 mg of vitamin C taken twice daily for three days reduces the time-weighted sum of pain-intensity difference (SPID) over 72 hours.

Methods:

The VICAMED study is a multicentre, triple-blind, randomized, placebo-controlled trial conducted in three university-affiliated EDs in Canada. Eligible participants are adults aged ≥18 years with MSK pain ≤48 hours, triaged to ambulatory care, and reporting pain >3/10. Exclusion criteria include recent vitamin C use, active cancer, recent analgesic intake, chronic pain treatment, and contraindications such as oxalate nephropathy or interactions with cyclosporine or warfarin. Participants receive an initial 900 mg dose of vitamin C or placebo in the ED, followed by twice-daily dosing for three days. Pain intensity is measured using validated 0-100 visual analog scales through electronic or paper diaries. A structured day-six follow-up captures missing data, analgesic use, adverse events, and health-related quality of life (EQ-5D-5L). The primary analysis uses ANCOVA adjusting for site and fracture status. Secondary analyses evaluate SPID72, analgesic consumption, time to significant pain relief, time to pain-free, proportion of days with adequate relief, adverse events, and healthcare utilization.

Based on a minimal clinically important difference of 13 points on a 0-100 pain scale and prior variance estimates, 204 participants are required for the primary outcome. The sample size for SPID72 will be finalized using pilot study data currently being analyzed. The study is powered to detect clinically meaningful differences in both immediate and short-term pain trajectories.

Expected Results:

If vitamin C demonstrates analgesic efficacy in acute MSK injuries, it could represent a safe, inexpensive, widely accessible, and opioid-sparing therapeutic option for ED patients, including those unable to use NSAIDs or acetaminophen. Given its favourable safety profile and over-the-counter availability, vitamin C has strong potential for rapid clinical integration. The research team's established collaborations within national emergency medicine networks will support broad dissemination and facilitate implementation across Canadian EDs.

03

Conditions studied

  • Pain, Acute

Keywords

  • Vitamin C
  • NSAID
  • Emergency department
  • Pain
  • RCT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years old
  2. Presenting to the ED with acute MSK pain of ≤ 48 hours duration at triage
  3. Verbal numerical rating scale pain intensity at triage of ≥ 4 on a 0-10 scale
  4. Triaged to the ambulatory section of the ED
  5. Able to communicate in French or English

Exclusion criteria

Exclusion Criteria:

  1. Usage of Vit C supplements in the last week
  2. Active cancer
  3. Treated with opioids for any pain within 24 hours prior to recruitment
  4. Treatment for chronic pain
  5. Unable to fill out a pain intensity diary or unavailable for follow-up
  6. Allergy to milk (lactose in the placebo) or Vit C
  7. Treated with cyclosporine or warfarin
  8. Pre-existing oxalate nephropathy, liver cirrhosis or hemochromatosis
  9. Hospitalized after clinician evaluation
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
204 participants (estimated)

Study arms

  • Experimental
    Vitamin C

    900 mg vitamin C taken orally twice a day

    Dietary Supplement: Vitamin C

  • Placebo comparator
    Placebo

    Placebo taken orally twice a day

    Other: Placebo

Interventions

  • Dietary supplementAscorbic AcidStudies of Ascorbic AcidAscorbic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    900 mg vitamin C taken orally twice a day (one in the morning and one in the evening) for a 3-day period after ED discharge for the treatment arm.

  • OtherPlacebo

    Placebo taken orally twice a day (one in the morning and one in the evening) for a 3-day period after ED discharge for the treatment arm.

06

What researchers measure

Primary outcomes

  1. Time-weighted sum of the pain-intensity difference (SPID)

    The primary outcome is the time-weighted sum of the pain-intensity difference (SPID) over the three-day treatment period on a 0-100 visual analog scale (VAS), where 0 is no pain and 100 the worst pain imaginable. The SPID accounts for both the magnitude of the pain change and its duration, producing a single value that reflects the patient's overall experience.

    Time frame: Three days

Secondary outcomes

  1. Difference in pain intensity

    The main secondary outcome is the difference in pain intensity, also measured on a 0-100 visual analog scale (VAS), where 0 is no pain and 100 the worst pain imaginable, between groups one hour after taking the first study drug in the ED.

    Time frame: Three days

  2. Consumption of as-needed pain medication

    Participants will be asked the name and the total amount of pain medication taken during the three-day follow-up.

    Time frame: Three days

  3. Time for significant pain relief

    Time for significant pain relief, reported in hours, is define in a 50% reduction in pain intensity.

    Time frame: Six days

  4. Time to pain-free

    Time, reported in hours, when pain reach 0 on a 0-100 visual analog scale (VAS), where 0 is no pain and 100 the worst pain imaginable

    Time frame: Six days

  5. Percentage of days with adequate relief

    To assess the proportion of days with adequate pain control, participants will answer a daily yes/no question regarding whether their pain was adequately relieved.

    Time frame: Six days

  6. New analgesic prescriptions

    Numbered and of new pain medication prescription received during follow-up, even opioids.

    Time frame: Three days

  7. Adverse events

    We will document during the day-six questionnaire if any of the following adverse events were experienced during the three-day period: nausea, vomiting, constipation, dizziness, drowsiness, sweating, weakness, or other adverse events.

    Time frame: Three days

  8. Quality of life improvement at six days

    Health-related quality of life will be assessed using the validated EQ-5D-5L questionnaire. EuroQol - five dimensions - 5 levels. It assesses five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) across 5 levels of severity-from no problems to extreme problems-providing a 5-digit health state profile used in clinical research and economic evaluations. Common Interpretation: 11111: Perfect health (Index 1.0). 55555: Worst health (lowest possible index).

    Time frame: Six days

  9. Quantity of Healthcare visits

    Participants will be asked about the number of all unscheduled or scheduled healthcare visits related to their initial pain condition during the day-6 questionnaire.

    Time frame: Six days

07

Study locations

1 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — IPD could be shared upon request, upon approval by our institution.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2028, 39 months after the start.

Of 425 non-industry interventional studies with no phase under Acute Pain, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 39 months is above that.

Counting every sponsor, half of 431 studies reached it within 11 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2024
First posted
Mar 12, 2024
StartActual
Sep 1, 2025
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06306183
Lead sponsor
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Collaborators
Hopital de l'Enfant-Jesus, The Ottawa Hospital
Responsible party
Raoul Daoust (Dr Emergency Medicine, Professor, Clinician Researcher, Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal) — Principal investigator
First posted
Mar 12, 2024
Start date
Sep 1, 2025
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Mar 2, 2026

Study contacts

Martin Marquis, MSc
Contact
martin.marquis.cnmtl@ssss.gouv.qc.ca
514-338-2222
Raoul Daoust, MD MSc
principal investigator · Université de Montréal

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ascorbic Acid

Start the discussion